501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

Liu, HL; Wei, PC; Zhang, QQ; Chen, ZZ; Aviszus, K; Downing, W; Peterson, S; Reynoso, L; Downey, GP; Frankel, SK; Kappler, J; Marrack, P; Zhang, GY

Liu, HL (corresponding author), Natl Jewish Hlth, Dept Immunol & Genom Med, Denver, CO 80206 USA.

MABS, 2021; 13 (1):